

# Takashi Suzuki

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7274326/publications.pdf>

Version: 2024-02-01

174  
papers

8,075  
citations

36303  
51  
h-index

64796  
79  
g-index

174  
all docs

174  
docs citations

174  
times ranked

8699  
citing authors

#	ARTICLE	IF	CITATIONS
1	Dissecting human adrenal androgen production. Trends in Endocrinology and Metabolism, 2002, 13, 234-239.	7.1	260
2	Androgen-responsive long noncoding RNA CTBP1-AS promotes prostate cancer. EMBO Journal, 2013, 32, 1665-1680.	7.8	243
3	Estrogen-Related Receptor $\hat{\pm}$ in Human Breast Carcinoma as a Potent Prognostic Factor. Cancer Research, 2004, 64, 4670-4676.	0.9	200
4	Intratumoral Estrogens and Estrogen Receptors in Human Nonâ€“Small Cell Lung Carcinoma. Clinical Cancer Research, 2008, 14, 4417-4426.	7.0	179
5	Accumulation of p62/ <scp>SQSTM</scp> 1 is associated with poor prognosis in patients with lung adenocarcinoma. Cancer Science, 2012, 103, 760-766.	3.9	177
6	Developmental changes in steroidogenic enzymes in human postnatal adrenal cortex: immunohistochemical studies. Clinical Endocrinology, 2000, 53, 739-747.	2.4	176
7	Physiology: Immunohistochemical distribution of progesterone, androgen and oestrogen receptors in the human ovary during the menstrual cycle: relationship to expression of steroidogenic enzymes. Human Reproduction, 1994, 9, 1589-1595.	0.9	162
8	Systemic Distribution of Steroid Sulfatase and Estrogen Sulfotransferase in Human Adult and Fetal Tissues. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 5760-5768.	3.6	156
9	Sex steroid-producing enzymes in human breast cancer. Endocrine-Related Cancer, 2005, 12, 701-720.	3.1	156
10	Progesterone Receptor in Nonâ€“Small Cell Lung Cancerâ€“A Potent Prognostic Factor and Possible Target for Endocrine Therapy. Cancer Research, 2005, 65, 6450-6458.	0.9	153
11	Estrogen sulfotransferase and steroid sulfatase in human breast carcinoma. Cancer Research, 2003, 63, 2762-70.	0.9	146
12	Expression of the Steroid and Xenobiotic Receptor and Its Possible Target Gene, Organic Anion Transporting Polypeptide-A, in Human Breast Carcinoma. Cancer Research, 2006, 66, 535-542.	0.9	132
13	Aromatase Localization in Human Breast Cancer Tissues: Possible Interactions between Intratumoral Stromal and Parenchymal Cells. Cancer Research, 2007, 67, 3945-3954.	0.9	117
14	The Orphan Nuclear Receptor NGFIB Regulates Transcription of 3Î²-Hydroxysteroid Dehydrogenase. Journal of Biological Chemistry, 2004, 279, 37622-37630.	3.4	113
15	Amyloid Precursor Protein Is a Primary Androgen Target Gene That Promotes Prostate Cancer Growth. Cancer Research, 2009, 69, 137-142.	0.9	105
16	Superoxide dismutase in normal cycling human ovaries: immunohistochemical localization and characterization. Fertility and Sterility, 1999, 72, 720-726.	1.0	98
17	Dysregulation of spliceosome gene expression in advanced prostate cancer by RNA-binding protein PSF. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 10461-10466.	7.1	93
18	Estrogen Regulates Tumor Growth Through a Nonclassical Pathway that Includes the Transcription Factors ERÎ² and KLF5. Science Signaling, 2011, 4, ra22.	3.6	92

#	ARTICLE	IF	CITATIONS
19	Nuclear cyclin B1 in human breast carcinoma as a potent prognostic factor. <i>Cancer Science</i> , 2007, 98, 644-651.	3.9	91
20	New development in intracrinology of breast carcinoma. <i>Breast Cancer</i> , 2006, 13, 129-136.	2.9	86
21	In situ androgen producing enzymes in human prostate cancer. <i>Endocrine-Related Cancer</i> , 2005, 12, 101-107.	3.1	84
22	Human liver-specific organic anion transporter is a potent prognostic factor for human breast carcinoma. <i>Cancer Science</i> , 2007, 98, 1570-1576.	3.9	83
23	TRIM25 enhances cell growth and cell survival by modulating p53 signals via interaction with G3BP2 in prostate cancer. <i>Oncogene</i> , 2018, 37, 2165-2180.	5.9	83
24	Steroid Sulfatase and Estrogen Sulfotransferase in Human Endometrial Carcinoma. <i>Clinical Cancer Research</i> , 2004, 10, 5850-5856.	7.0	81
25	In situ estrogen production and its regulation in human breast carcinoma: From endocrinology to intracrinology. <i>Pathology International</i> , 2009, 59, 777-789.	1.3	80
26	Colocalization of 11 $\beta$ -Hydroxysteroid Dehydrogenase Type II and Mineralocorticoid Receptor in Human Epithelia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997, 82, 3859-3863.	3.6	75
27	Interactions between prostaglandin E(2), liver receptor homologue-1, and aromatase in breast cancer. <i>Cancer Research</i> , 2005, 65, 657-63.	0.9	75
28	Adrenal changes associated with adrenarche. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2009, 10, 19-26.	5.7	74
29	Novel prognostic protein markers of resectable pancreatic cancer identified by coupled shotgun and targeted proteomics using formalin-fixed paraffin-embedded tissues. <i>International Journal of Cancer</i> , 2013, 132, 1368-1382.	5.1	74
30	Association of USP10 with G3BP2 Inhibits p53 Signaling and Contributes to Poor Outcome in Prostate Cancer. <i>Molecular Cancer Research</i> , 2018, 16, 846-856.	3.4	74
31	Intracrinology of estrogens and androgens in breast carcinoma. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2008, 108, 181-185.	2.5	73
32	Aromatase inhibitor treatment of breast cancer cells increases the expression of let-7f, a microRNA targeting CYP19A1. <i>Journal of Pathology</i> , 2012, 227, 357-366.	4.5	73
33	5 $\alpha$ -Reductase type 1 and aromatase in breast carcinoma as regulators of in situ androgen production. <i>International Journal of Cancer</i> , 2007, 120, 285-291.	5.1	71
34	Development of the human adrenal zona reticularis: morphometric and immunohistochemical studies from birth to adolescence. <i>Journal of Endocrinology</i> , 2009, 203, 241-252.	2.6	71
35	Androgenic pathway in triple negative invasive ductal tumors: Its correlation with tumor cell proliferation. <i>Cancer Science</i> , 2013, 104, 639-646.	3.9	71
36	Intratumoral concentration of sex steroids and expression of sex steroid-producing enzymes in ductal carcinoma in situ of human breast. <i>Endocrine-Related Cancer</i> , 2008, 15, 113-124.	3.1	70

#	ARTICLE	IF	CITATIONS
37	RNA-binding protein NONO promotes breast cancer proliferation by post-transcriptional regulation of <i>SKP2</i> and <i>E2F8</i> . <i>Cancer Science</i> , 2020, 111, 148-159.	3.9	67
38	Estrogen-Responsive Finger Protein as a New Potential Biomarker for Breast Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 6148-6154.	7.0	65
39	Steroid sulfatase and estrogen sulfotransferase in normal human tissue and breast carcinoma. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2003, 86, 449-454.	2.5	64
40	Increased intratumoral androgens in human breast carcinoma following aromatase inhibitor exemestane treatment. <i>Endocrine-Related Cancer</i> , 2010, 17, 415-430.	3.1	64
41	5 $\alpha$ -Reductases in Human Breast Carcinoma: Possible Modulator of In Situ Androgenic Actions <sup>1</sup> . <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 2250-2257.	3.6	61
42	Highly concordant coexpression of aromatase and estrogen receptor $\beta$ in non-small cell lung cancer. <i>Human Pathology</i> , 2010, 41, 190-198.	2.0	61
43	Sex steroid receptors in rheumatoid arthritis. <i>Clinical Science</i> , 2004, 106, 293-300.	4.3	59
44	Nucleobindin 2 in human breast carcinoma as a potent prognostic factor. <i>Cancer Science</i> , 2012, 103, 136-143.	3.9	59
45	Hexokinase <i>HK2</i> in breast carcinoma: A potent prognostic factor associated with hypoxia-inducible factor <i>HIF-1</i> and <i>Ki-67</i> . <i>Cancer Science</i> , 2013, 104, 1380-1388.	3.9	59
46	Urocortin and Corticotropin-Releasing Factor Receptor Expression in Normal Cycling Human Ovaries <sup>1</sup> . <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 1362-1369.	3.6	56
47	Steroid Sulfotransferase 2A1 Gene Transcription Is Regulated by Steroidogenic Factor 1 and GATA-6 in the Human Adrenal. <i>Molecular Endocrinology</i> , 2005, 19, 184-197.	3.7	56
48	Steroid Sulfatase and Estrogen Sulfotransferase in Colon Carcinoma: Regulators of Intratumoral Estrogen Concentrations and Potent Prognostic Factors. <i>Cancer Research</i> , 2009, 69, 914-922.	0.9	56
49	Steroid sulfatase and estrogen sulfotransferase in human prostate cancer. <i>Prostate</i> , 2006, 66, 1005-1012.	2.3	55
50	NRF2 immunolocalization in human breast cancer patients as a prognostic factor. <i>Endocrine-Related Cancer</i> , 2014, 21, 241-252.	3.1	55
51	Cancer-associated fibroblasts secrete Wnt2 to promote cancer progression in colorectal cancer. <i>Cancer Medicine</i> , 2019, 8, 6370-6382.	2.8	55
52	Runt-related transcription factor 2 in human colon carcinoma: A potent prognostic factor associated with estrogen receptor. <i>International Journal of Cancer</i> , 2012, 131, 2284-2293.	5.1	53
53	Immunolocalization of liver receptor homologue-1 (LRH-1) in human breast carcinoma: Possible regulator of in situ steroidogenesis. <i>Cancer Letters</i> , 2006, 244, 24-33.	7.2	52
54	17 $\beta$ -Hydroxysteroid Dehydrogenase Types 1 and 2 in Human Placenta: An Immunohistochemical Study with Correlation to Placental Development <sup>1</sup> . <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 3710-3715.	3.6	51

#	ARTICLE	IF	CITATIONS
55	Amyloid precursor protein in human breast cancer: An androgen-induced gene associated with cell proliferation. <i>Cancer Science</i> , 2013, 104, 1532-1538.	3.9	51
56	Effects of steroid hormones on vascular functions. <i>Microscopy Research and Technique</i> , 2003, 60, 76-84.	2.2	50
57	17 $\beta$ -Hydroxysteroid dehydrogenases in human endometrium and its disorders. <i>Molecular and Cellular Endocrinology</i> , 2006, 248, 136-140.	3.2	50
58	PSF Promotes ER-Positive Breast Cancer Progression via Posttranscriptional Regulation of <i>ESR1</i> and <i>SCFD2</i> . <i>Cancer Research</i> , 2020, 80, 2230-2242.	0.9	50
59	Early growth responsive gene 3 in human breast carcinoma: a regulator of estrogen-mediated invasion and a potent prognostic factor. <i>Endocrine-Related Cancer</i> , 2007, 14, 279-292.	3.1	49
60	Intratumoral Localization of Aromatase and Interaction between Stromal and Parenchymal Cells in the Non-Small Cell Lung Carcinoma Microenvironment. <i>Cancer Research</i> , 2010, 70, 6659-6669.	0.9	49
61	11 $\beta$ -Hydroxysteroid Dehydrogenase Type 2 in Human Lung: Possible Regulator of Mineralocorticoid Action. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 4022-4025.	3.6	48
62	Increased androgen receptor activity and cell proliferation in aromatase inhibitor-resistant breast carcinoma. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2014, 144, 513-522.	2.5	48
63	Transcriptional Regulation of Dehydroepiandrosterone Sulfotransferase (SULT2A1) by Estrogen-Related Receptor $\alpha$ . <i>Endocrinology</i> , 2005, 146, 3605-3613.	2.8	47
64	The Analyses of 17 $\beta$ -Hydroxysteroid Dehydrogenase Isozymes in Human Endometrial Hyperplasia and Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 3436-3443.	3.6	46
65	Effects of aromatase inhibitors on human osteoblast and osteoblast-like cells: A possible androgenic bone protective effects induced by exemestane. <i>Bone</i> , 2007, 40, 876-887.	2.9	46
66	<i>ESR1</i> -Stabilizing Long Noncoding RNA <i>TMPO-AS1</i> Promotes Hormone-Refractory Breast Cancer Progression. <i>Molecular and Cellular Biology</i> , 2019, 39, .	2.3	46
67	TACC2 Is an Androgen-Responsive Cell Cycle Regulator Promoting Androgen-Mediated and Castration-Resistant Growth of Prostate Cancer. <i>Molecular Endocrinology</i> , 2012, 26, 748-761.	3.7	45
68	Sex steroid receptors expression and hormone-induced cell proliferation in human osteosarcoma. <i>Cancer Science</i> , 2008, 99, 518-523.	3.9	44
69	Increased estrogen sulfatase (STS) and 17 $\beta$ -hydroxysteroid dehydrogenase type 1 (17 $\beta$ -HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2010, 120, 639-648.	2.5	44
70	Urocortin 1, Urocortin 3/Stresscopin, and Corticotropin-Releasing Factor Receptors in Human Adrenal and Its Disorders. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 4671-4678.	3.6	43
71	Nur-Related Factor 1 and Nerve Growth Factor-Induced Clone B in Human Adrenal Cortex and Its Disorders. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 4113-4118.	3.6	42
72	Steroid Sulfatase and Estrogen Sulfotransferase in the Atherosclerotic Human Aorta. <i>American Journal of Pathology</i> , 2003, 163, 1329-1339.	3.8	40

#	ARTICLE	IF	CITATIONS
73	Expression of Urocortin and Corticotropin-Releasing Factor Receptor Subtypes in the Human Heart. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 340-346.	3.6	40
74	KrÄppel-like factor 5 in human breast carcinoma: a potent prognostic factor induced by androgens. Endocrine-Related Cancer, 2012, 19, 741-750.	3.1	39
75	<scp>OLFM</scp>4, <scp>LY</scp>6D and S100A7 as potent markers for distant metastasis in estrogen receptorâ€positive breast carcinoma. Cancer Science, 2018, 109, 3350-3359.	3.9	39
76	Immunohistochemical distribution of 11Î²-hydroxysteroid dehydrogenase in human eye. Molecular and Cellular Endocrinology, 2001, 173, 121-125.	3.2	38
77	17Î²-Hydroxysteroid Dehydrogenase Type 1 and 2 Expression in the Human Fetus1. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 410-416.	3.6	37
78	Nudixâ€type motif 2 in human breast carcinoma: A potent prognostic factor associated with cell proliferation. International Journal of Cancer, 2011, 128, 1770-1782.	5.1	37
79	Interaction with adipocyte stromal cells induces breast cancer malignancy via S100A7 upregulation in breast cancer microenvironment. Breast Cancer Research, 2017, 19, 70.	5.0	37
80	Progesterone receptor isoforms as a prognostic marker in human endometrial carcinoma. Cancer Science, 2006, 97, 1308-1314.	3.9	36
81	17Î²-Hydroxysteroid Dehydrogenase Type 12 in Human Breast Carcinoma: A Prognostic Factor via Potential Regulation of Fatty Acid Synthesis. Cancer Research, 2009, 69, 1392-1399.	0.9	36
82	Chicken ovalbumin upstream promoter transcription factor II in human breast carcinoma: Possible regulator of lymphangiogenesis via vascular endothelial growth factorâ€C expression. Cancer Science, 2009, 100, 639-645.	3.9	36
83	Androgens in human breast carcinoma. Medical Molecular Morphology, 2010, 43, 75-81.	1.0	36
84	Steroid sulfatase and estrogen sulfotransferase in human carcinomas. Molecular and Cellular Endocrinology, 2011, 340, 148-153.	3.2	36
85	Messenger Ribonucleic Acidin SituHybridization Analysis of Estrogen Receptors Î± and Î² in Human Breast Carcinoma1. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 781-785.	3.6	34
86	Intracrine mechanism of estrogen synthesis in breast cancer. Biomedicine and Pharmacotherapy, 2003, 57, 460-462.	5.6	34
87	In situ production of sex steroids in human breast carcinoma. Medical Molecular Morphology, 2007, 40, 121-127.	1.0	34
88	BUB1 Immunolocalization in Breast Carcinoma: Its Nuclear Localization as a Potent Prognostic Factor of the Patients. Hormones and Cancer, 2013, 4, 92-102.	4.9	34
89	Hexokinase 2 in colorectal cancer: a potent prognostic factor associated with glycolysis, proliferation and migration. Histology and Histopathology, 2017, 32, 351-360.	0.7	34
90	11Î²-Hydroxysteroid Dehydrogenase Type II and Mineralocorticoid Receptor in Human Placenta1. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 1306-1309.	3.6	32

#	ARTICLE	IF	CITATIONS
91	Aromatase in Human Breast Carcinoma as a Key Regulator of Intratumoral Sex Steroid Concentrations. <i>Endocrine Journal</i> , 2008, 55, 455-463.	1.6	32
92	An induction of microRNA, miR-7 through estrogen treatment in breast carcinoma. <i>Journal of Translational Medicine</i> , 2012, 10, S2.	4.4	32
93	The role of 5 $\alpha$ -reductase type 1 associated with intratumoral dihydrotestosterone concentrations in human endometrial carcinoma. <i>Molecular and Cellular Endocrinology</i> , 2015, 401, 56-64.	3.2	32
94	11 $\beta$ -Hydroxysteroid Dehydrogenase Type 2 and Mineralocorticoid Receptor in Human Fetal Development. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 1453-1458.	3.6	31
95	Localization of Steroidogenesis and Steroid Receptors in Human Corpus Luteum. <i>Seminars in Reproductive Medicine</i> , 1997, 15, 345-352.	1.1	30
96	ALDH1A1 in patientâ€derived bladder cancer spheroids activates retinoic acid signaling leading to TUBB3 overexpression and tumor progression. <i>International Journal of Cancer</i> , 2020, 146, 1099-1113.	5.1	30
97	Retinoid Receptors in Human Breast Carcinoma: Possible Modulators of in Situ Estrogen Metabolism. <i>Breast Cancer Research and Treatment</i> , 2001, 65, 31-40.	2.5	29
98	TRIM44 promotes cell proliferation and migration by inhibiting FRK in renal cell carcinoma. <i>Cancer Science</i> , 2020, 111, 881-890.	3.9	29
99	Intratumoral estrogen production in breast carcinoma: significance of aromatase. <i>Breast Cancer</i> , 2008, 15, 270-277.	2.9	28
100	17 $\beta$ -Hydroxysteroid Dehydrogenases in Human Breast Cancer. <i>Annals of the New York Academy of Sciences</i> , 2009, 1155, 25-32.	3.8	28
101	New Developments in Intracrinology of Human Breast Cancer. <i>Annals of the New York Academy of Sciences</i> , 2009, 1155, 76-79.	3.8	28
102	Controversies of aromatase localization in human breast cancerâ€Stromal versus parenchymal cells. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2007, 106, 97-101.	2.5	27
103	L-type amino acid transporter 1 is associated with chemoresistance in breast cancer via the promotion of amino acid metabolism. <i>Scientific Reports</i> , 2021, 11, 589.	3.3	27
104	Comparative effects of raloxifene, tamoxifen and estradiol on human osteoblasts in vitro: Estrogen receptor dependent or independent pathways of raloxifene. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2009, 113, 281-289.	2.5	26
105	Expression of (pro)renin receptor in breast cancers and its effect on cancer cell proliferation. <i>Biomedical Research</i> , 2014, 35, 117-126.	0.9	25
106	Increased 5 $\alpha$ -Reductase Type 2 Expression in Human Breast Carcinoma following Aromatase Inhibitor Therapy: The Correlation with Decreased Tumor Cell Proliferation. <i>Hormones and Cancer</i> , 2011, 2, 73-81.	4.9	24
107	In situ androgen and estrogen biosynthesis in endometrial cancer: focus on androgen actions and intratumoral production. <i>Endocrine-Related Cancer</i> , 2016, 23, R323-R335.	3.1	24
108	TRIM47 activates NF- $\kappa$ B signaling via PKC- $\zeta$ /PKD3 stabilization and contributes to endocrine therapy resistance in breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	24



#	ARTICLE	IF	CITATIONS
109	Immunolocalization of estrogen-producing and metabolizing enzymes in benign breast disease: Comparison with normal breast and breast carcinoma. <i>Cancer Science</i> , 2010, 101, 2286-2292.	3.9	23
110	Associations of obesity and physical activity with serum and intratumoral sex steroid hormone levels among postmenopausal women with breast cancer: analysis of paired serum and tumor tissue samples. <i>Breast Cancer Research and Treatment</i> , 2017, 162, 115-125.	2.5	23
111	Wnt5a in cancer-associated fibroblasts promotes colorectal cancer progression. <i>Biochemical and Biophysical Research Communications</i> , 2021, 568, 37-42.	2.1	23
112	In situ detection of estrogen receptor dimers in breast carcinoma cells in archival materials using proximity ligation assay (PLA). <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2017, 165, 159-169.	2.5	22
113	In situ production of estrogens in human breast carcinoma. <i>Breast Cancer</i> , 2002, 9, 296-302.	2.9	21
114	Role of Local 11 $\beta$ -Hydroxysteroid Dehydrogenase Type 2 Expression in Determining the Phenotype of Adrenal Adenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 864-870.	3.6	21
115	The AP-1 family member FOS blocks transcriptional activity of the nuclear receptor steroidogenic factor 1. <i>Journal of Cell Science</i> , 2010, 123, 3956-3965.	2.0	21
116	Intratumoral localization and activity of 17 $\beta$ -hydroxysteroid dehydrogenase type 1 in non-small cell lung cancer: a potent prognostic factor. <i>Journal of Translational Medicine</i> , 2013, 11, 167.	4.4	21
117	p62/sequestosome 1 in human colorectal carcinoma as a potent prognostic predictor associated with cell proliferation. <i>Cancer Medicine</i> , 2017, 6, 1264-1274.	2.8	21
118	COBLL1 modulates cell morphology and facilitates androgen receptor genomic binding in advanced prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 4975-4980.	7.1	21
119	Abnormal expression of miR-41 in breast carcinoma as a potent prognostic factor. <i>Cancer Science</i> , 2015, 106, 1642-1650.	3.9	20
120	11 $\beta$ -Prostaglandin F $_{2\alpha}$ , a bioactive metabolite catalyzed by AKR1C3, stimulates prostaglandin F receptor and induces slug expression in breast cancer. <i>Molecular and Cellular Endocrinology</i> , 2015, 413, 236-247.	3.2	20
121	Subtype-specific collaborative transcription factor networks are promoted by OCT4 in the progression of prostate cancer. <i>Nature Communications</i> , 2021, 12, 3766.	12.8	20
122	Benign cortisol-secreting adrenocortical adenomas produce small amounts of androgens. <i>Clinical Endocrinology</i> , 2007, 66, 778-788.	2.4	19
123	Ovarian epithelial carcinoma with estrogen-producing stroma. <i>Pathology International</i> , 2007, 57, 285-290.	1.3	19
124	Intracrinology of sex steroids in ductal carcinoma in situ (DCIS) of human breast: Comparison to invasive ductal carcinoma (IDC) and non-neoplastic breast. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2009, 114, 68-71.	2.5	19
125	Steroid and xenobiotic receptor in human esophageal squamous cell carcinoma: A potent prognostic factor. <i>Cancer Science</i> , 2010, 101, 543-549.	3.9	19
126	TACC2 (transforming acidic coiled-coil protein 2) in breast carcinoma as a potent prognostic predictor associated with cell proliferation. <i>Cancer Medicine</i> , 2016, 5, 1973-1982.	2.8	19



#	ARTICLE	IF	CITATIONS
127	Roles of Aryl Hydrocarbon Receptor in Aromatase-Dependent Cell Proliferation in Human Osteoblasts. International Journal of Molecular Sciences, 2017, 18, 2159.	4.1	19
128	Increased expression of 11 $\beta$ -hydroxysteroid dehydrogenase type 2 in the lungs of patients with acute respiratory distress syndrome. Pathology International, 2003, 53, 751-756.	1.3	18
129	Relaxin 2/RXFP1 Signaling Induces Cell Invasion via the $\beta$ <sup>2</sup> -Catenin Pathway in Endometrial Cancer. International Journal of Molecular Sciences, 2018, 19, 2438.	4.1	18
130	Systemic distribution of estrogen-responsive finger protein (Efp) in human tissues. Molecular and Cellular Endocrinology, 2004, 218, 147-153.	3.2	17
131	Steroid and xenobiotic receptor-mediated effects of bisphenol A on human osteoblasts. Life Sciences, 2016, 155, 29-35.	4.3	17
132	Inflammatory Mediators Down-Regulate 11 $\beta$ -Hydroxysteroid Dehydrogenase Type 2 in a Human Lung Epithelial Cell Line BEAS-2B and the Rat Lung. Tohoku Journal of Experimental Medicine, 2005, 207, 293-301.	1.2	16
133	GATA4 immunolocalization in breast carcinoma as a potent prognostic predictor. Cancer Science, 2014, 105, 600-607.	3.9	16
134	Aryl hydrocarbon receptor induced intratumoral aromatase in breast cancer. Breast Cancer Research and Treatment, 2017, 161, 399-407.	2.5	16
135	ARHGAP15 in Human Breast Carcinoma: A Potent Tumor Suppressor Regulated by Androgens. International Journal of Molecular Sciences, 2018, 19, 804.	4.1	16
136	Stromal CCL5 Promotes Breast Cancer Progression by Interacting with CCR3 in Tumor Cells. International Journal of Molecular Sciences, 2021, 22, 1918.	4.1	16
137	<sc>CITED</sc>2 in breast carcinoma as a potent prognostic predictor associated with proliferation, migration and chemoresistance. Cancer Science, 2016, 107, 1898-1908.	3.9	15
138	Hormonal Regulation of Patient-Derived Endometrial Cancer Stem-like Cells Generated by Three-Dimensional Culture. Endocrinology, 2019, 160, 1895-1906.	2.8	15
139	Cytochrome c1 in ductal carcinoma <i>in situ</i> of breast associated with proliferation and comedo necrosis. Cancer Science, 2017, 108, 1510-1519.	3.9	14
140	Targeting Amino Acid Metabolic Reprogramming via L-Type Amino Acid Transporter 1 (LAT1) for Endocrine-Resistant Breast Cancer. Cancers, 2021, 13, 4375.	3.7	14
141	Intratumoral Estrogen Concentration and Expression of Estrogen-Induced Genes in Male Breast Carcinoma: Comparison with Female Breast Carcinoma. Hormones and Cancer, 2013, 4, 1-11.	4.9	13
142	Immunolocalization of Corticotropin-Releasing Hormone (CRH) and Its Receptors (CRHR1 and CRHR2) in Human Endometrial Carcinoma. International Journal of Gynecological Cancer, 2014, 24, 1549-1557.	2.5	13
143	17 $\beta$ -Hydroxysteroid Dehydrogenase Type 2 Expression Is Induced by Androgen Signaling in Endometrial Cancer. International Journal of Molecular Sciences, 2018, 19, 1139.	4.1	13
144	Rac1 activation in human breast carcinoma as a prognostic factor associated with therapeutic resistance. Breast Cancer, 2020, 27, 919-928.	2.9	13

#	ARTICLE	IF	CITATIONS
145	Functional inhibition of cancer stemness-related protein DPP4 rescues tyrosine kinase inhibitor resistance in renal cell carcinoma. <i>Oncogene</i> , 2021, 40, 3899-3913.	5.9	13
146	Estrogen Inhibits Cell Proliferation through In situ Production in Human Thymoma. <i>Clinical Cancer Research</i> , 2005, 11, 6495-6504.	7.0	12
147	Androgen and androgen-metabolizing enzymes in metastasized lymph nodes of breast cancer. <i>Human Pathology</i> , 2013, 44, 2338-2345.	2.0	12
148	Tissue concentrations of estrogens and aromatase immunolocalization in interstitial pneumonia of human lung. <i>Molecular and Cellular Endocrinology</i> , 2014, 392, 136-143.	3.2	12
149	Progesterone Metabolism in Human Leukemic Monoblast U937 Cells.. <i>Endocrine Journal</i> , 2002, 49, 539-546.	1.6	11
150	Oestrogen-induced genes in ductal carcinoma in situ: their comparison with invasive ductal carcinoma. <i>Endocrine-Related Cancer</i> , 2012, 19, 485-496.	3.1	11
151	Human 3 $\beta$ -hydroxysteroid dehydrogenase type 1 in human breast cancer: clinical significance and prognostic associations. <i>Cancer Medicine</i> , 2016, 5, 1405-1415.	2.8	11
152	Targeting Epigenetic and Posttranscriptional Gene Regulation by PSF Impairs Hormone Therapy-Refractory Cancer Growth. <i>Cancer Research</i> , 2021, 81, 3495-3508.	0.9	11
153	Analysis of gene expression induced by diethylstilbestrol (DES) in human primitive Mullerian duct cells using microarray. <i>Cancer Letters</i> , 2005, 220, 197-210.	7.2	10
154	Aromatase and in situ estrogen production in DCIS (ductal carcinoma in situ) of human breast. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2010, 118, 242-245.	2.5	10
155	The interplay of endocrine therapy, steroid pathways and therapeutic resistance: Importance of androgen in breast carcinoma. <i>Molecular and Cellular Endocrinology</i> , 2018, 466, 31-37.	3.2	10
156	A metabolic profile of routine needle biopsies identified tumor type specific metabolic signatures for breast cancer stratification: a pilot study. <i>Metabolomics</i> , 2019, 15, 147.	3.0	10
157	Isoforms of IDH in breast carcinoma: IDH2 as a potent prognostic factor associated with proliferation in estrogen-receptor positive cases. <i>Breast Cancer</i> , 2021, 28, 915-926.	2.9	10
158	Analysis for Localization of Steroid Sulfatase in Human Tissues. <i>Methods in Enzymology</i> , 2005, 400, 303-316.	1.0	9
159	Intratumoral androgen metabolism and actions in invasive lobular carcinoma of the breast. <i>Cancer Science</i> , 2014, 105, 1503-1509.	3.9	9
160	Intratumoral estrogen production and actions in luminal A type invasive lobular and ductal carcinomas. <i>Breast Cancer Research and Treatment</i> , 2016, 156, 45-55.	2.5	8
161	Forkhead Box I1 in Breast Carcinoma as a Potent Prognostic Factor. <i>Acta Histochemica Et Cytochemica</i> , 2021, 54, 123-130.	1.6	8
162	Ductal carcinoma in situ and related lesions of the breast: Recent advances in pathology practice. <i>Breast Cancer</i> , 2004, 11, 325-333.	2.9	7

#	ARTICLE	IF	CITATIONS
163	Cyclin-dependent kinase-specific activity predicts the prognosis of stage I and stage II non-small cell lung cancer. BMC Cancer, 2014, 14, 755.	2.6	7
164	Co-expression of nuclear heterogeneous nuclear ribonucleic protein K and estrogen receptor $\beta$ in endometrial cancer. Pathology Research and Practice, 2022, 231, 153795.	2.3	7
165	Retinoic Acid Receptor $\beta$ : A Potential Therapeutic Target in Retinoic Acid Treatment of Endometrial Cancer. International Journal of Gynecological Cancer, 2017, 27, 643-650.	2.5	6
166	PSPC1 is a potential prognostic marker for hormone-dependent breast cancer patients and modulates RNA processing of ESR1 and SCFD2. Scientific Reports, 2022, 12, .	3.3	6
167	Retinoid receptors in human esophageal squamous cell carcinoma: Retinoid X receptor as a potent prognostic factor. Pathology International, 2011, 61, 401-408.	1.3	5
168	Immunohistochemical analysis of aromatase in metastatic lymph nodes of breast cancer. Pathology International, 2013, 63, 20-28.	1.3	5
169	Identification and Functional Characterization of a Novel Androgen Receptor Coregulator, EAP1. Journal of the Endocrine Society, 2021, 5, bvab150.	0.2	4
170	Cytochrome c1 as a favorable prognostic marker in estrogen receptor-positive breast carcinoma. Histology and Histopathology, 2019, 34, 1365-1375.	0.7	4
171	Immunolocalization of CD80 and CD86 in Non-Small Cell Lung Carcinoma: CD80 as a Potent Prognostic Factor. Acta Histochemica Et Cytochemica, 2022, 55, 25-35.	1.6	4
172	D-2-hydroxyglutarate dehydrogenase in breast carcinoma as a potent prognostic marker associated with proliferation. Histology and Histopathology, 2021, , 18362.	0.7	3
173	Clinicopathological and Preclinical Patient-Derived Model Studies Define High Expression of NRN1 as a Diagnostic and Therapeutic Target for Clear Cell Renal Cell Carcinoma. Frontiers in Oncology, 2021, 11, 758503.	2.8	1
174	New development in intracrinology of breast carcinoma: therapeutic horizons after aromatase inhibitors. Expert Review of Endocrinology and Metabolism, 2007, 2, 367-374.	2.4	0